

Endorectal Ultrasound-Guided Fine-Needle Aspiration: A Useful Diagnostic Tool for Perirectal and Intraluminal Lesions

Zahra Maleki^a Yener Erozan^a Susan Geddes^b Qing Kay Li^b

^aDepartment of Pathology, The Johns Hopkins Hospital, and ^bDepartment of Pathology, Johns Hopkins Bayview Medical Center, Baltimore, Md., USA

Key Words

Endorectal endoscopic ultrasound • Fine-needle aspiration • Colorectal adenocarcinoma

Abstract

Objectives: Endorectal endoscopic ultrasound (ERUS) allows highly detailed assessment of the rectal wall layers and visualization of the extraluminal structures. Herein, we study the utility of ERUS fine-needle aspiration (FNA) to evaluate perirectal lesions. **Study Design:** Forty-nine ERUS-FNAs were retrieved from the cytopathology archives of The Johns Hopkins Hospital. The cytology slides, corresponding histology, immunohistochemistry when available, and clinical data were reviewed. **Results:** The aspirated material showed malignant (n = 24), benign (n = 19), atypical (n = 3), carcinoid tumor (n = 1), and nondiagnostic conditions (n = 2). The past medical history of 36 cases was significant for carcinomas. The primary site of the tumors included colorectal, urinary bladder, prostate, pancreas, gallbladder, ovary, and female lower genital tract. Statistical analysis for endoscopic ultrasonography FNA showed 87% sensitivity, 100% specificity, diagnostic accuracy of 90%, and a positive predictive value of 100% and a negative predictive value of 77%. **Conclusion:** ERUS-FNA can be utilized for: (1) accurate staging of colorec-

tal adenocarcinomas by evaluation of nodal metastasis, depth of transmural tumor invasion and local tumor spread to perirectal fat, (2) prevention of aggressive surgical intervention in benign conditions, (3) providing diagnostic material for ancillary studies, and (4) evaluation of perirectal lesions with a more accurate method by combining imaging and histology.

Copyright © 2012 S. Karger AG, Basel

Introduction

Endoscopic ultrasonography (EUS) is a combination of endoscopy and intraluminal sonography. Due to the short distance to the target lesions, EUS yields high resolution images using a high frequency transducer. Endorectal endoscopic ultrasound (ERUS) represents one of the most significant developments in endoscopy in the last 20 years, and it is routinely used in daily clinical practice for diagnosis and staging of malignancies of the colorectal region and its surrounding structures such as

This paper was partially presented at the USCAP 2011 Annual Meeting in San Antonio, Tex., USA, February 26–March 4, 2011.

KARGER

Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

© 2012 S. Karger AG, Basel
0001-5547/13/0571-0009\$38.00/0

Accessible online at:
www.karger.com/acy

Correspondence to: Dr. Zahra Maleki
Department of Pathology, The Johns Hopkins Hospital
600 N. Wolfe St.
Baltimore, MD 21287 (USA)
E-Mail Zmaleki1@jhmi.edu

the prostate and bladder. ERUS allows highly detailed assessment of the rectal wall layers as well as visualization of the extra-luminal structures. It can be used to confirm malignancy in suspicious lesions as well as to identify and confirm nodal metastasis, tumor recurrence, or metastatic spread. Assessment of the depth of tumor penetration provides information for T staging in the TNM classification, and the ultrasonographic staging is suggested by the prefix 'u' [1]. For N staging, involvement is usually suspected if a lymph node is over 5 mm in diameter, round, and hypoechoic, features which may differentiate it from inflammatory nodes [2]. Furthermore, a tissue diagnosis of malignancy can be established by performing ERUS fine-needle aspiration (FNA) [3]. Herein, 49 ERUS-FNA specimens from 47 patients and their corresponding forceps biopsies or resected tissue specimens over a 22-year period have retrospectively been reviewed. ERUS-FNA findings have been reviewed to illustrate the utility of this relatively new technique in the diagnosis, staging, treatment, and prognosis of malignant neoplasms and the subsequent prevention of unnecessary aggressive surgical intervention in benign conditions.

Materials and Methods

Institutional Review Board approval for this study was obtained. The cytopathology archives of The Johns Hopkins Hospital were retrospectively searched for ERUS-FNA cases performed at this institution between January 1, 1990, and January 1, 2012. There were 49 perirectal FNA specimens from 47 patients obtained under ERUS guidance. EUS-FNAs were performed by gastroenterologists in an endoscopy unit or a radiologist in an ultrasound unit. A pathologist or cytotechnologist was present during the procedure for on-site evaluation of specimen adequacy when it was requested. Multiple aspirations were performed on each case. The aspirated material was immediately smeared on glass slides. The air-dried smears were stained with Diff-Quik stain for immediate on-site evaluation. Additional smeared slides were fixed in 95% ethanol and stained with Papanicolaou stain. The remaining material in the needle was rinsed with Hank's balanced salt solution immediately after the procedure. The paraffin cell blocks were made of rinsed material and 4- μ m sections were stained with hematoxylin-eosin (H&E). In addition to cell blocks, cytology slides were prepared using a liquid-based preparation method, e.g. cytospins. The number of passes, specimen adequacy on site, and the presence of a cytotechnologist or cytopathologist were recorded. Performance of the procedure by either a radiologist or a gastroenterologist and prophylactic administration of antibiotics was also noted. Immunohistochemical stains were done as needed on cell block material. On final cytopathologic examination 'unsatisfactory' diagnoses were rendered in cases in which the specimen was paucicellular. Perirectal FNA slides and their corresponding tissue biopsies or resections

were reviewed by the authors and their cytology-histology diagnoses were correlated. Clinical information including patients' demographics, medical history including prior malignancy, endoscopy, cytology, and histology reports, as well as imaging studies and the patients' subsequent treatment and follow-up, were reviewed. The size of the mass lesions, the number of passes, and on-site adequacy interpretations were recorded and correlated.

Results

Forty-nine specimens from 47 patients of perirectal or intraluminal FNAs were reviewed. There were 22 males and 25 females (M:F ratio 0.88). Their ages ranged from 17 to 79 years (mean = 55.6 years). Two patients had two specimens each with histologic confirmation. One patient had a perirectal lymph node and a soft tissue mass which were diagnosed as a benign lymph node and poorly differentiated squamous cell carcinoma, respectively. The second patient had a rectal nodule which was biopsied twice and diagnosed benign both times. The microscopic examination of aspirated material was noted as malignant (n = 24), benign (n = 19), markedly atypical cells suspicious for carcinoma (n = 3), carcinoid tumor (n = 1), and nondiagnostic (n = 2).

Malignant cases (table 1) were colorectal adenocarcinoma (n = 9) (fig. 1), urothelial carcinoma (n = 64) (fig. 2), squamous cell carcinoma (n = 4), prostatic adenocarcinoma (n = 1), metastatic adenocarcinoma of the lung (n = 1), metastatic adenocarcinoma of the gallbladder (n = 1), metastatic carcinoma of the breast (n = 1), and metastatic carcinoma of the pancreas (n = 1). Twenty-one of 24 cases had concurrent core biopsy or surgical resection confirming the cytologic diagnosis of adenocarcinoma. One of 24 patients who had no history of carcinoma was diagnosed with metastatic poorly differentiated lung adenocarcinoma on ERUS-FNA. The patient had a large lung mass, multiple lytic lesions of bone, and a perirectal mass.

Immunohistochemical stains performed on cell blocks were available for 7 cases with malignant cytology. CK7, CK20, CDX2, PSA, PSAP, CEA, chromogranin, synaptophysin, and CD56 were commonly used immunostains. CK7, CK20, CDX2, and CEA are utilized to diagnose metastatic gallbladder carcinoma, pancreatic adenocarcinoma, and colonic adenocarcinoma. PSA and PSAP are used to differentiate prostatic adenocarcinoma, and neuroendocrine markers are used to differentiate neuroendocrine features in colonic adenocarcinoma and a poorly differentiated squamous cell carcinoma with basaloid features.

Table 1. Cytologic findings of ERUS-FNA in patients with a known history of carcinoma

ERUS-FNA diagnosis	Histologic diagnosis	History of cancer	Imaging diagnosis	Clinical significance	Change in treatment
Colorectal adenocarcinoma	Consistent with histology	Colorectal adenocarcinoma	CT/hematoma, or soft tissue	Metastasis	None
Colorectal adenocarcinoma	Colorectal adenocarcinoma	Colorectal adenocarcinoma	CT/negative for mass	N0 staging to N1	Chemoradiation prior to surgery
Colorectal adenocarcinoma	Consistent with histology	Colorectal adenocarcinoma	CT/negative	N0 staging to N1	Chemoradiation prior to surgery
Colorectal adenocarcinoma	Colorectal adenocarcinoma	Colorectal adenocarcinoma	CT/mass favor carcinoma	T3N0M0	Chemoradiation prior to surgery
Colorectal adenocarcinoma	Colorectal adenocarcinoma	Colorectal adenocarcinoma	Not available	First time Dx	Surgery followed by chemoradiation
Colorectal adenocarcinoma	Colorectal adenocarcinoma	Colorectal adenocarcinoma	MRI/colorectal wall thickening	Recurrence	Surgery followed by chemoradiation
Colorectal adenocarcinoma	Colorectal adenocarcinoma	Colorectal adenocarcinoma	CT/recurrence, soft tissue mass	Recurrence	Chemoradiation
Colorectal adenocarcinoma	Colorectal adenocarcinoma	Colorectal adenocarcinoma	CT/sarcoma or GIST	T2 staging to T3	More radiation
Colorectal adenocarcinoma	Colorectal adenocarcinoma	Colorectal adenocarcinoma	CT/metastasis	Recurrence	Chemoradiation
Urothelial carcinoma	Consistent with histology	Urothelial carcinoma	CT/metastasis or recurrence	Metastasis, N0 to N2	No follow-up
Urothelial carcinoma	Urothelial carcinoma	Urothelial carcinoma	CT/tumor infiltration	Metastasis	Chemotherapy
Urothelial carcinoma	Urothelial carcinoma	Urothelial carcinoma	CT/inflammation	Recurrence	Diverting ostomy, chemotherapy
Urothelial carcinoma	Urothelial carcinoma	Urothelial carcinoma	CT/inflammatory process	Recurrence	Diverting ostomy, chemotherapy
Prostatic adenocarcinoma	Prostatic adenocarcinoma	Prostatic adenocarcinoma	CT/lymphadenopathy	N0 staging to N1	New androgen suppression
Urothelial carcinoma	Urothelial carcinoma	Urothelial carcinoma and prostatic adenocarcinoma	CT/carcinoma	Recurrence	Chemotherapy
Urothelial carcinoma	Urothelial carcinoma	Urothelial carcinoma	CT/carcinoma	Recurrence	Chemotherapy
Poorly differentiated adenocarcinoma	None	None	CT/large lung mass and metastasis	Metastasis, end stage cancer	Hospice
Squamous cell carcinoma	Squamous cell carcinoma	Squamous cell carcinoma	CT/carcinoma	Recurrence	Radiation
Squamous cell carcinoma	Squamous cell carcinoma	Squamous cell carcinoma	CT/mass	Recurrence, T2 staging to T3	Chemoradiation
Squamous cell carcinoma	Squamous cell carcinoma	Squamous cell carcinoma	CT/mass	Recurrence, T2 staging to T3	Chemoradiation
Squamous cell carcinoma	Consistent with histology	Squamous cell carcinoma	CT/mass	Recurrence vulvar carcinoma	Radiation
Adenocarcinoma, gallbladder primary	Adenocarcinoma	Gallbladder adenocarcinoma	CT/drop metastasis	Metastasis	Add radiation and start chemotherapy again
Carcinoma, breast primary	Carcinoma, breast primary	Breast ductal adenocarcinoma	Not available	Metastasis	Enrolled in clinical trial
Adenocarcinoma, pancreas primary	Adenocarcinoma, pancreas primary	Pancreatic adenocarcinoma	CT/colorectal wall thickening	Metastasis	Chemotherapy
Fibrous tissue, benign epithelium	Benign fibrous tissue	Colorectal adenocarcinoma	CT/colorectal wall thickening	Benign finding	None
Reactive glandular epithelium	Tubular adenoma	Colorectal adenocarcinoma	CT/colorectal wall thickening	T1 tumor	Preservation of anal sphincter
Lymphocytes, benign epithelium	Crohn's disease	Colorectal adenocarcinoma	Endoscopy/mass	Benign finding	None

Table 1 (continued)

ERUS-FNA diagnosis	Histologic diagnosis	History of cancer	Imaging diagnosis	Clinical significance	Change in treatment
Benign epithelium and debris	Submucosal fibrosis	Colorectal adenocarcinoma	Endoscopy/mass	Benign finding	None
Fluid, benign epithelium	Fluid collection	Colorectal adenocarcinoma	Endoscopy/mass	Benign finding	None
Benign epithelium	Benign colonic mucosa	Colorectal adenocarcinoma	CT/recurrence	Benign finding	No follow-up
Fibrous tissue, benign epithelium,	Inflammatory polyp	Gastric adenocarcinoma	CT/wall thickening, suspicious	Benign finding	None
Nondiagnostic	Sarcomatous carcinoma	Prostatic adenocarcinoma	CT/mass	Recurrence	Chemoradiation
Mucin, benign epithelium	Submucosal lipoma	Urothelial carcinoma	Endoscopy/submucosal lipoma	Nonmalignant	Rectosigmoid resection
Mucinous cyst, atypical cells	None	Ovarian carcinoma	Endoscopy/cyst in muscularis propria	Recurrence	Chemotherapy
Markedly atypical epithelial cells	High-grade squamous intraepithelial lesion	Anal intraepithelial high-grade lesion	Endoscopy/mass	Recurrence	Follow-up
Markedly atypical epithelial cells	Radiation associated atypia	Squamous cell carcinoma/cervix	Endoscopy/mass	Benign finding	None
Markedly atypical epithelial cells	Colorectal adenocarcinoma	Colorectal carcinoma	Endoscopy/mass	Malignant finding	Rectosigmoid resection

Among 24 cases with malignant cytology, CT images favored a benign process such as fluid, hematoma, inflammation, and soft tissue mass in 5 cases.

Nineteen aspirated cases were consistent with benign findings (table 2); 18 had concurrent biopsy or subsequent histologic diagnosis. Benign diagnoses were confirmed in 16/18 cases. The histologic diagnoses included endometriosis, submucosal lipoma, submucosal fibrosis, inflammatory polyp, Crohn's disease, perirectal abscess, retrorectal cyst, prolapsed associated changes, cyst fluid, and epithelial cells with focal atypia in a background of mucin. Core biopsies of 2/18 cases were poorly differentiated carcinoma with sarcomatous features in one case and tubular adenoma in the other case. One case missed the follow-up without having a tissue biopsy. Ten of 19 cases with benign cytology had a clinical history of histologically proven carcinoma (6 colorectal adenocarcinomas, 1 gastric adenocarcinoma, 1 prostatic adenocarcinoma, 1 urothelial carcinoma, and 1 ovarian carcinoma).

Among 19 cases with benign cytology, CT images were suspicious for recurrent malignancy in 2 cases, i.e. inflammatory polyp and benign epithelial cells on core biopsy, respectively.

Three cases were diagnosed as markedly atypical epithelial cells suspicious for carcinoma. All three cases had histologic diagnosis. One was adenocarcinoma arising in a tubular adenoma. The second case had a high-grade squamous intraepithelial lesion (AIN III) and inflammatory polyp on core biopsies. The third case had a history of invasive squamous cell carcinoma of the cervix and showed squamous cell atypia due to radiation effects on cytology.

Two cases had a histologically proven history of rectal carcinoid. The FNA of a perirectal mass in one of them was consistent with carcinoid and the second case showed colonic mucosa.

One case was nondiagnostic due to scant cellularity. Tissue biopsy showed tubular adenoma.

We also correlated the size of the lesions and the number of passes.

The number of passes ranged from 1 to 10 (mean = 3.5 passes). The mass size was recorded for 31 cases. The mass lesions measured 0.6–10 cm in diameter (mean = 3.15 cm). The malignant masses ranged from 0.6 to 10 cm (mean = 2.1 cm) and benign masses ranged from 0.9 to 6.8 cm (mean = 3.07 cm). No significant correlation was noted between the number of passes and the size of

Table 2. Finding in cases with no history of malignancy

ERUS-FNA diagnosis	Histologic diagnosis	Imaging diagnosis	Clinical significance	Change in treatment
Few spindle cells, benign colonic mucosa (n = 2)	Colitis with prolapsed associated changes	Endoscopy/submucosal mass	Benign findings	Noninvasive treatment
Mature nucleated and anucleated squamous cells	Abscess	CT/abscess	Benign findings	Abscess drainage
Inflammation and benign epithelium	Fibrous tissue with inflammation	CT/mass, MRI/mass	Benign findings	Conservative surgery of pelvic mass
Prostatic tissue, seminal vesicles	Prostatic tissue, seminal vesicles	MRI/rectal wall thickening favor infection	Benign findings	Mycobacterial and bacterial culture
Few spindle cells mucin, benign colonic mucosa,	Fibroblastic proliferation	Endoscopy/submucosal hard mass	Benign findings	Conservative surgery of pelvic mass
Benign glandular epithelium	Extensive endometriosis	Endoscopy and CT/multiple masses	None	Radical surgery
Benign squamous and colonic epithelium	Benign retrorectal cyst	MRI/cyst	Nonaggressive surgery	Hysterectomy
Benign glandular epithelium	Endometriosis involving the bowl	Endoscopy/mass	None	Rectosigmoid resection
Nondiagnostic	Tubular adenoma	Endoscopy/mass	Staging	Resection
Carcinoid	History of carcinoid	Endoscopy/small submucosal mass	Nonmalignant	No additional work up
Benign epithelial cells	History of carcinoid	Endoscopy/lymph node	Benign findings	None

the lesions (table 3). Thirty-three aspirations were done by gastroenterologists in an endoscopy unit and 14 aspirations were performed by interventional radiologists in an ultrasound unit. Thirteen patients received prophylactic antibiotic prior to the procedure, i.e. 9 by gastroenterologists and 4 by radiologists. Forty-five specimens were evaluated on site by a pathologist or a cytotechnologist for adequacy. On-site evaluation was not requested by gastroenterologists for 4 procedures including one rectal adenocarcinoma, one fluid collection status post-rectal cancer resection next to the anastomosis site, one tubular adenoma, and one invasive squamous cell carcinoma of the cervix. All 24 malignant cases were adequate.

Imaging studies included CT scans, MRI, and EUS. On imaging studies the cases presented as perirectal masses which were either solid (n = 43) or cystic (n = 4). Thirty-three cases were designated as a distinct mass and 14 cases as thickening of the intestinal wall. Four cases were cystic on imaging. Cytomorphologic findings included acute and chronic inflammation and debris,

Table 3. Correlation of size of the mass and number of passes

	Small masses (2.5 cm or smaller)	Larger masses (greater than 2.5 cm)
Minimum mass size, cm	0.6	2.9
Maximum mass size, cm	2.5	10
Average mass size, cm	1.52	4.17
Minimum number of passes	2	2
Maximum number of passes	6	10
Average number of passes	3.1	3.0
Total	12	19

anucleated squamous cells consistent with an epidermal inclusion cyst (fig. 3) and, confirmed on histology, benign appearing colonic mucosa, prostatic cells, and seminal vesicles; one was nondiagnostic due to scant cellularity.




Fig. 1. Rectal adenocarcinoma showing a sheet of malignant cells with hyperchromatic nuclei, irregular nuclear membranes, and prominent nucleoli. Papanicolaou stain. $\times 400$.




Fig. 2. Urothelial carcinoma with a hypercellular smear consisting of epithelial cells with moderate pleomorphism. Note the extremely large cells in the center. Papanicolaou stain. $\times 400$.




Fig. 3. Epidermal inclusion cyst showing anucleated squamous cells with debris in the background. Diff-Quik stain. $\times 200$.




Fig. 4. CDX2 immunostain on a cell block highlights metastatic colorectal carcinoma in a perirectal lymph node. Immunostain. $\times 200$.

Three patients had no further follow-up in our institution (one with local recurrence of urothelial carcinoma to perirectal tissue, and two with benign epithelial cells). The third patient had a history of colorectal adenocarcinoma.

All patients tolerated the procedure well and none of them reported any immediate or delayed complications resulting from the procedure.

Clinical Impact

ERUS-FNA findings had a significant clinical impact in all cases that were followed up at our institution (table 4). A new diagnosis of metastatic lung adenocarcinoma was made in 1 case with no prior history of malignancy. Tumor recurrence was confirmed in 6 cases and tumor metastasis was confirmed in 9 cases. Chemotherapy, ra-

Table 4. Clinical impact of cytologic diagnosis of perirectal lesions on cancer staging or cytologic confirmation of tumor recurrence in patients diagnosed with cancer

Primary neoplasms	Diagnostic confirmation	Change in cancer stage	Benign diagnosis
Colorectal adenocarcinoma (n = 16)	7	3	6
Urothelial carcinoma (n = 7)	5	1	1
Squamous cell carcinoma (n = 5)	2	2	1
Prostatic adenocarcinoma (n = 1)	–	1	–
Adenocarcinoma of the gallbladder (n = 1)	–	1	–
Adenocarcinoma of the lung (n = 1)	–	1	–
Lobular carcinoma of the breast (n = 1)	–	1	–
Adenocarcinoma of the pancreas (n = 1)	–	1	–
Gastric adenocarcinoma (n = 1)	–	–	1
Ovarian carcinoma (n = 1)	1	–	–

diation, or chemoradiation was given to all but 2 cases of carcinoma (one went to hospice and the other had recurrent urothelial carcinoma and had no follow-up in our institution).

Tumor staging for colorectal carcinomas was changed in 8 cases based on cytologic diagnosis of malignancy including T2 to T3 in 4 cases, N0 to N1 in 3 cases, and N0 to N2 in 1 case. Based on positive findings for malignancy, 4 patients with colorectal adenocarcinoma were treated with chemoradiation followed by surgery. Chemoradiation was started for a patient diagnosed with metastasis from adenocarcinoma of the gallbladder. The amount and field of radiation was changed in one patient due to a change of T staging from T2 to T3. A patient with metastatic breast carcinoma to the perirectal area was started on a clinical trial. The patient with a large lung mass, clinical evidence of widespread metastatic carcinoma, and metastatic lung adenocarcinoma to the perirectal area went to hospice. ERUS-FNA provided adequate diagnostic material on cell block to perform immunostains to confirm recurrence or metastasis (fig. 4).

The rectal sphincter was preserved in a patient with benign diagnosis of perirectal FNA. The patient underwent transanal resection for adenocarcinoma arising in the tubular adenoma. Four cases with no history of malignancy and benign appearing cells on cytology underwent surgery due to presence of mass lesions or severe pain. One had rectosigmoid resection and was diagnosed with a large submucosal lipoma. The second case was a young woman with a prolonged history of abdominal pain, several FNAs and core biopsies with benign findings and imaging highly suspicious for malignancy. She underwent hysterectomy, rectal resection, and numerous

pelvic nodule resections. All resected organs were extensively affected by endometriosis. The third case was a 35-year-old woman with a history of severe rectal and abdominal pain, and endometriosis of the umbilicus. She had a rectosigmoid resection and was diagnosed with endometriosis involving the rectal wall with associated serosal adhesions. The fourth case had a large pelvic mass suspicious for a neoplasm on imaging. Fibrous tissue with inflammation was found upon conservative surgery of the pelvic mass. Four of 19 cases with benign cytology had subsequent core biopsies which were negative for tumor in all 4 cases. Finally, of the cases with marked epithelial atypia, one revealed adenocarcinoma arising in tubular adenoma, one showed extensive high grade squamous lesions, and the third case displayed changes consistent with radiation effects.

Statistical Analysis

Statistical analysis for EUS-FNA showed 87% sensitivity, 100% specificity, a diagnostic accuracy of 90%, a positive predictive value of 100%, and a negative predictive value of 77%.

Discussion

EUS was first introduced to clinical practice in 1980 [4]. ERUS-FNA was first developed in the early 1990s to enhance the diagnostic capabilities of EUS by providing additional pathological findings [5]. Curved linear array echoendoscopes use an electronic transducer and they offer the ability to perform interventional procedures such as FNA under real-time visualization [6]. New tech-

niques that have contributed significantly to the evolution of ERUS include three-dimensional ERUS [7], high-frequency miniprbes, transrectal ultrasound-guided biopsy techniques, and hydrogen peroxide-enhanced endosonography [8]. ERUS-FNA is usually well tolerated under conscious sedation on an outpatient basis similar to other endoscopic procedures [6]. It can be performed by a gastroenterologist or radiologist either in an endoscopy unit or an ultrasound unit. Transrectal EUS-guided biopsy is a safe and efficient method for tissue sampling of perirectal lesions. The risk of tumor seeding along the biopsy tract is very small, with only rare cases reported in the literature [9, 10]. Its complication rate is 1–2%, which is similar to that of computed tomography (CT) or percutaneous ultrasound-guided needle aspirations [9, 11]. The major reported complications are bleeding and infections in cystic lesions. Most reported complications are from EUS-FNA of the upper gastrointestinal tract or pancreas [12].

Bacteremia occurs after ERUS-FNA at a similar rate to that of colonoscopy but it does not warrant the prophylactic administration of antibiotics [13]. In our study, there were some patients who received prophylactic antibiotics. Contraindications are inability to clearly visualize a lesion or a tumor mass or vessel interposed in the path between the needle and the target.

Our study did not find any significant correlation between the number of passes and the size of the mass. However, Jhala et al. [14] reported a mean of 2.5 passes (range 1–9 passes) for small lesions (≤ 25 mm) and a mean of 4.5 passes (range 1–11 passes) for large lesions (>25 mm) [14]. Specimens obtained could easily be processed for immunohistochemical staining as there were multiple immunostains for 7 of our cases and potentially for molecular analysis.

In Japan, the current indications for EUS-FNA include: differentiating between benign and malignant lesions, staging of cancer, and to establish the endoscopic diagnosis of malignancy before chemotherapy and/or radiation therapy [15]. Perirectal lymph nodes or masses, submucosal masses, and suspected recurrent cancers in and adjacent to surgical anastomoses are potential targets for ERUS-FNA. Sasaki et al. [16] reported an overall success rate of 95.5% with EUS-FNA to detect benign and malignant lesions. However, the success rate for imaging investigation alone without the histologic findings was 81.8% [16]. Jhala et al. [14] reported EUS-FNA as a highly effective technique to obtain samples with an overall diagnostic yield of 96% from both small and large lesions without affecting the sensitivity, specificity, or diagnostic

accuracy. Knight et al. [17] reported overall sensitivity, specificity, and positive and negative predictive values of EUS-FNA of 89, 79, 89, and 79%. Our study shows a slightly lower sensitivity of 87% and a higher specificity of 100%, a diagnostic accuracy of 90%, a positive predictive value of 100%, and negative predictive value of 77%.

Accurate staging of rectal and anal carcinomas is crucial for surgical treatment and neoadjuvant chemotherapy planning. Accurate preoperative staging determines both the type of surgery performed and the decision to use preoperative chemoradiation. Inaccurate staging tends to result from overstaging because of associated peritumoral inflammation and difficulty distinguishing malignant from benign reactive lymphadenopathies. In addition, tumor stenosis prevents full staging in approximately 14% of patients. ERUS-FNA is used in clinical practice to evaluate submucosal lesions, depth of invasion in colorectal cancer, tumor invasion in perirectal fat, and nodal status. The prognosis of rectal cancer correlates with pathological staging at the time of diagnosis. Preoperative chemoradiation in locally advanced rectal cancers improves local control and is associated with an increased rate of sphincter preservation in patients with low-lying cancer [18–20]. In our study, 5 patients had preoperative chemoradiation followed by surgery, and the anal sphincter was preserved in one case with low-lying cancer.

Comparative studies have demonstrated that ERUS is superior to CT in staging accuracy and equivalent to MRI for T and N staging. Overall, ERUS accuracy in numerous studies ranges from 80 to 95% for T staging and 70 to 75% for N staging. These levels are slightly higher than the respective 75–85% for T staging and 60–70% for N staging observed for magnetic resonance imaging (MRI) [21–24] and 65–75% and 55–65%, respectively, for helical CT [22]. The overall sensitivities and specificities for malignancy reported in the literature range from 82 to 96% and 94 to 100%, respectively [5, 25, 26]. Preoperative ERUS-FNA may enhance identification of extramesenteric lymph node metastasis outside of the standard radiation field or mesorectal resection margin and may affect the surgical or chemoradiation treatment strategy [27]. ERUS is more accurate to distinguish between benign tumors and invasive carcinomas and between tumors localized to the rectal wall versus tumors with transmural invasion [28]. FNA especially improves the accuracy of endorectal ultrasound in the diagnosis of recurrent rectal cancer [29–32]. Restaging after neoadjuvant chemoradiation therapy is compromised by the effects of chemoradiation such as inflammation, edema, necrosis, and fibrosis. Postradiation changes such as fibrosis are difficult to distinguish

from the residual tumor, and thus poor staging results mainly from overstaging [1, 33]. ERUS-FNA allows cytologic examination of any suspicious lymph node or intramural mass. ERUS-FNA is also a practical method to approach pelvic masses as discussed in our findings [34, 35].

The limitations of ERUS are that: (1) it is heavily operator dependent, (2) patient acceptability is low particularly in painful conditions [36], (3) it cannot be performed in stenotic tumors, (4) it has limited depth of penetration, and (5) it has a limited field of view [37, 33]. A potential pitfall is overstaging of the tumor. Peritumoral inflammation, hemorrhage, and desmoplastic changes can potentially affect accuracy and result in tumor overstaging [38].

In conclusion, our study illustrates that ERUS-FNA of perirectal lesions is a safe, minimally invasive, and well-tolerated procedure that provides valuable information

which affects patient management. It is superior to imaging alone in both benign and malignant lesions because it provides cytology material to evaluate the nature of the lesion [30]. It is extremely helpful for accurate staging of colorectal adenocarcinomas and to detect metastatic carcinomas. Immunostains can be performed on cell block material as needed. Benign findings such as inflammation or fibrous tissue can be worked up in a conservative way in cancer-free patients and can prevent aggressive surgery, chemoradiation, or overstaging in cancer patients.

Disclosure Statement

None.

References

- 1 Edelman BR, Weiser MR: Endorectal ultrasound: its role in the diagnosis and treatment of rectal cancer. *Clin Colon Rectal Surg* 2008;21:167–177.
- 2 Schaffzin DM, Wong WD: Endorectal ultrasound in the preoperative evaluation of rectal cancer. *Clin Colorectal Cancer* 2004;4:124–132.
- 3 Cartana ET, Parvu D, Saftoiu A: Endoscopic ultrasound: current role and future perspectives in managing rectal cancer patients. *J Gastrointest Liver Dis* 2011;20:407–413.
- 4 DiMugno EP, Buxton JL, Regan PT, Hattery RR, Wilson DA, Suarez JR, Green PS: Ultrasonic endoscope. *Lancet* 1980;1:629–631.
- 5 Williams DB, Sahai AV, Aabakken L, Penman ID, van Velse A, Webb J, Wilson M, Hoffman BJ, Hawes RH: Endoscopic ultrasound guided fine needle aspiration biopsy: a large single centre experience. *Gut* 1999;44:720–726.
- 6 Lennon AM, Penman ID: Endoscopic ultrasound in cancer staging. *Br Med Bull* 2007;84:81–98.
- 7 Giovannini M, Bories E, Pesenti C, Moutardier V, Lelong B, Delpero JR: Three-dimensional endorectal ultrasound using a new freehand software program: results in 35 patients with rectal cancer. *Endoscopy* 2006;38:339–343.
- 8 Giovannini M, Ardizzone S: Anorectal ultrasound for neoplastic and inflammatory lesions. *Best Pract Res Clin Gastroenterol* 2006;20:113–135.
- 9 Hirooka Y, Goto H, Itoh A, Hashimoto S, Niwa K, Ishikawa H, Okada N, Itoh T, Kawashima H: Case of intraductal papillary mucinous tumor in which endosonography-guided fine-needle aspiration biopsy caused dissemination. *J Gastroenterol Hepatol* 2003;18:1323–1324.
- 10 Shah JN, Fraker D, Guerry D, Feldman M, Kochman ML: Melanoma seeding of an EUS-guided fine needle track. *Gastrointest Endosc* 2004;59:923–924.
- 11 Ballo MS, Guy CD: Percutaneous fine-needle aspiration of gastrointestinal wall lesions with image guidance. *Diagn Cytopathol* 2001;24:16–20.
- 12 Wiersema MJ, Vilman P, Giovannini M, Chang KJ, Wiersema LM: Endosonography-guided fine-needle aspiration biopsy: diagnostic accuracy and complication assessment. *Gastroenterology* 1997;112:1087–1095.
- 13 Levy MJ, Norton ID, Clain JE, Enders FB, Gleeson F, Limburg PJ, Nelson H, Rajan E, Topazian MD, Wang KK, Wiersema MJ, Wilson WR: Prospective study of bacteremia and complications With EUS FNA of rectal and perirectal lesions. *Clin Gastroenterol Hepatol* 2007;5:684–689.
- 14 Jhala NC, Jhala D, Eltoun I, Vickers SM, Wilcox CM, Chhieng DC, Eloubeidi MA: Endoscopic ultrasound-guided fine-needle aspiration biopsy: a powerful tool to obtain samples from small lesions. *Cancer* 2004;102:239–246.
- 15 Yamao K, Bhatia V, Mizuno N, Sawaki A, Shimizu Y, Irisawa A: Interventional endoscopic ultrasonography. *J Gastroenterol Hepatol* 2009;24:509–519.
- 16 Sasaki Y, Niwa Y, Hirooka Y, Ohmiya N, Itoh A, Ando N, Miyahara R, Furuta S, Goto H: The use of endoscopic ultrasound-guided fine-needle aspiration for investigation of submucosal and extrinsic masses of the colon and rectum. *Endoscopy* 2005;37:154–160.
- 17 Knight CS, Eloubeidi MA, Crowe R, Jhala NC, Jhala DN, Chhieng DC, Eltoun IA: Utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of colorectal carcinoma. *Diagn Cytopathol* 2011, E-pub ahead of print.
- 18 Maor Y, Nadler M, Barshack I, Zmora O, Koller M, Kundel Y, Fidler H, Bar-Meir S, Avidan B: Endoscopic ultrasound staging of rectal cancer: diagnostic value before and following chemoradiation. *J Gastroenterol Hepatol* 2006;21:454–458.
- 19 Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF and others: Preoperative versus postoperative chemoradiotherapy for rectal cancer. *N Engl J Med* 2004;351:1731–1740.
- 20 Harewood GC: Assessment of clinical impact of endoscopic ultrasound on rectal cancer. *Am J Gastroenterol* 2004;99:623–627.
- 21 Ptok H, Marusch F, Meyer F, Wendling P, Wenisch HJ, Sendt W, Manger T, Lippert H, Gasteringer I: Feasibility and accuracy of TRUS in the pre-treatment staging for rectal carcinoma in general practice. *Eur J Surg Oncol* 2006;32:420–425.
- 22 Siddiqui AA, Fayiga Y, Huerta S: The role of endoscopic ultrasound in the evaluation of rectal cancer. *Int Semin Surg Oncol* 2006;3:36.

- 23 Meyenberger C, Huch Boni RA, Bertschinger P, Zala GF, Klotz HP, Krestin GP: Endoscopic ultrasound and endorectal magnetic resonance imaging: a prospective, comparative study for preoperative staging and follow-up of rectal cancer. *Endoscopy* 1995;27:469–479.
- 24 Friel CM, Cromwell JW, Marra C, Madoff RD, Rothenberger DA, Garcia-Aguilar J: Salvage radical surgery after failed local excision for early rectal cancer. *Dis Colon Rectum* 2002;45:875–879.
- 25 Chang KJ, Wiersema MJ: Endoscopic ultrasound-guided fine-needle aspiration biopsy and interventional endoscopic ultrasonography: emerging technologies. *Gastrointest Endosc Clin N Am* 1997;7:221–235.
- 26 Raut CP, Grau AM, Staerckel GA, Kaw M, Tamm EP, Wolff RA, Vauthey JN, Lee JE, Pisters PW, Evans DB: Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. *J Gastrointest Surg* 2003;7:118–126, discussion 127–128.
- 27 Gleeson FC, Clain JE, Rajan E, Topazian MD, Wang KK, Levy MJ: EUS-FNA assessment of extramesenteric lymph node status in primary rectal cancer. *Gastrointest Endosc* 2011;74:897–905.
- 28 Garcia-Aguilar J, Pollack J, Lee SH, Hernandez de Anda E, Mellgren A, Wong WD, Finne CO, Rothenberger DA, Madoff RD: Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. *Dis Colon Rectum* 2002;45:10–15.
- 29 Layfield LJ, Gopez EV: Percutaneous image-guided fine-needle aspiration of peritoneal lesions. *Diagn Cytopathol* 2003;28:6–12.
- 30 Hunerbein M, Totkas S, Moesta KT, Ulmer C, Handke T, Schlag PM: The role of transrectal ultrasound-guided biopsy in the postoperative follow-up of patients with rectal cancer. *Surgery* 2001;129:164–169.
- 31 Morken JJ, Baxter NN, Madoff RD, Finne CO 3rd: Endorectal ultrasound-directed biopsy: a useful technique to detect local recurrence of rectal cancer. *Int J Colorectal Dis* 2006;21:258–264.
- 32 Woodward T, Menke D: Diagnosis of recurrent rectal carcinoma by EUS-guided fine-needle aspiration. *Gastrointest Endosc* 2000;51:223–225.
- 33 Bhutani MS: Recent developments in the role of endoscopic ultrasonography in diseases of the colon and rectum. *Curr Opin Gastroenterol* 2007;23:67–73.
- 34 Sailer M, Bussen D, Fein M, Freys S, Debus SE, Thiede A, Fuchs KH: Endoscopic ultrasound-guided transrectal biopsies of pelvic tumors. *J Gastrointest Surg* 2002;6:342–346.
- 35 Takahashi Y, Irisawa A, Bhutani MS, Hikichi T, Takagi T, Shibukawa G, Wakatsuki T, Imamura H, Sato A, Sato M, Ikeda T, Suzuki R, Obara K, Hashimoto Y, Watanabe K, Ohira H: Two cases of retroperitoneal liposarcoma diagnosed using endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA). *Diagn Ther Endosc* 2009;2009:673194.
- 36 Saranovic D, Barisic G, Krivokapic Z, Masulovic D, Djuric-Stefanovic A: Endoanal ultrasound evaluation of anorectal diseases and disorders: technique, indications, results and limitations. *Eur J Radiol* 2007;61:480–489.
- 37 Kav T, Bayraktar Y: How useful is rectal endosonography in the staging of rectal cancer? *World J Gastroenterol* 2010;16:691–697.
- 38 Mackay SG, Pager CK, Joseph D, Stewart PJ, Solomon MJ: Assessment of the accuracy of transrectal ultrasonography in anorectal neoplasia. *Br J Surg* 2003;90:346–350.